Mammalian AMP-activated protein kinase presents strong structural and functional similarities with the yeast sucrose non-fermenting 1 (Snf1) kinase involved in the derepression of glucose-repressed genes. It is now clearly established that AMP-activated protein kinase in the liver decreases glycolytic/lipogenic gene expression as well as genes involved in hepatic glucose production. This is achieved through a decreased transcriptional efficiency of transcription factors such as sterol-regulatory-element-binding protein-1c, carbohydrate-response-element-binding protein, hepatocyte nuclear factor 4α or forkhead-related protein.
Glucose regulation of hepatic gene expression
In order to survive, living organisms must continuously adapt their metabolism to the nutritional environment. The regulation of metabolic pathways involves rapid modulation of the activity of specific proteins but also, on a longer-term basis, changes in their quantity. This is often achieved by modulating the transcription rate of their genes. In the liver, some genes are particularly sensitive to changes in the nutritional environment. They belong to the glycolytic/lipogenic pathway, involved in the utilization of glucose by the liver and the ultimate synthesis of fatty acids from this substrate [1] . Whereas glucokinase, the first enzyme of the glycolytic pathway in the liver, is exclusively dependent on a high insulin concentration for its expression [2] , a subset of glycolytic/lipogenic genes in the liver requires increased insulin and glucose concentrations to be fully expressed [3] . This is the case for liver pyruvate kinase (L-PK), fatty acid synthase (FAS), Spot 14 (S14), a gene which encodes a small acidic polypeptide related to lipogenesis, and acetyl-CoA carboxylase [4] [5] [6] [7] . The regulation of these genes involves the stimulation of their transcription rate. In the absence of glucose, insulin by itself, although necessary, is unable to induce their expression.
A role for AMP-activated protein kinase in glycolytic/lipogenic gene expression
A potential involvement of phosphorylation/dephosphorylation mechanisms in the control of gene expression by glucose has been described for the S14 and FAS genes [8] . The AMP-activated protein kinase (AMPK) is a potential candidate as a protein kinase involved in the regulation of glucose-activated genes. AMPK is a heterotrimeric complex comprising a catalytic subunit (α) and two regulatory subunits (β and γ ) [9] . Several isoforms with tissuespecific expression have been described for each subunit. A significant clue regarding a possible role for AMPK in the regulation of gene transcription came from the finding that it is structurally and functionally related to the yeast protein kinase complex sucrose non-fermenting 1 (Snf1) [10] . In yeast, the transcription of a number of genes is repressed by high concentrations of glucose [11] . The kinase activity of Snf1 is essential for the derepression of these genes in yeast grown under conditions of glucose limitation. Snf1 (catalytic subunit) forms a heterotrimeric complex with two regulatory subunits [9] . The amino acid sequences of the mammalian AMPK subunits are highly related to their counterparts in Snf1 and the kinases show functional similarities [10] . Taken together, these findings led us and others to speculate that AMPK may be involved in regulating gene transcription in mammals. Evidence that this is the case came from studies in which AMPK was activated in primary cultured hepatocytes by incubation with 5-amino-4-imidazolecarboxamide riboside (AICAR), leading to the inhibition of glucose/insulin-induced FAS, L-PK and S14 gene expression [12, 13] . Since AICAR probably has effects other than a mere activation of AMPK, AMPK activity was also modulated by an adenovirusmediated overexpression of a constitutively active form of the catalytic subunit (α). The constitutively active form of AMPK was obtained by deleting the auto-inhibitory region and the β-and γ -binding regions of the α subunit and then replacing Thr-172 with a negatively charged amino acid to mimic the activating phosphorylation by an AMPK kinase [14] . When AMPK activity was increased in cultured hepatocytes using this active form of the kinase an inhibition of FAS, L-PK and S14 gene expression was again obtained. These results imply that AMPK is involved in the repression of insulin/glucoseactivated genes. Since an increase in AMPK activity inhibits insulin/glucose-activated gene transcription, it follows that a decrease in AMPK activity could be part of a mechanism involved in the stimulation of gene transcription by glucose. To test this hypothesis, a dominant negative form of the kinase was used. The dominant negative form consists of a dead kinase cloned into an adenoviral vector. When overexpressed in hepatocytes it replaces the wild-type α subunit (both α1 and α2 isoforms) in the heterotrimeric complex, which becomes inactive. In hepatocytes grown in 5 mM glucose, the dominant negative form of the kinase led to a marked decrease in the activity of AMPK [14] . However, inhibition of AMPK activity had no detectable effect on any of the aforementioned genes. In addition, changing the glucose concentration in the medium of cultured hepatocytes from 5 to 25 mM had no inhibitory effect on endogenous AMPK activity [12, 14] . Taken together, these results rule out the possibility that, in the liver, glucose exerts its effects on gene expression by directly inhibiting AMPK. Thus in the liver AMPK is involved in the inhibition of insulin/glucoseactivated gene expression but not in the induction pathway. In this situation, AMPK opposes the effect of insulin on gene expression.
It must be pointed out that in a β-cell line, raising the glucose concentration from 3 to 30 mM induces a 30-40% decrease in AMPK activity and this is concomitant with increased promoter activity of a transfected L-PK promoter. In these cells, inhibiting the AMPK activity at 3 mM glucose by injection of a specific AMPK antibody mimics the effect of a high glucose concentration on the L-PK promoter activity [15] . It is thus possible that in cells which are especially sensitive to low glucose concentrations, such as β-cells, an inhibition of AMPK activity at increased glucose concentration is part of the mechanism activating gene transcription.
The transcription factors involved in the insulin/glucose regulation of glycolytic/lipogenic genes have recently been elucidated. Insulin action involves the sterol-regulatoryelement-binding protein 1c (SREBP-1c), a transcription factor belonging to a family of proteins originally identified as being involved in the regulation of genes by the cellular availability of cholesterol [16] . SREBP-1c is synthesized as a precursor form bound to the endoplasmic reticulum and nuclear membranes. The N-terminal fragment of approx. 480 amino acids is in fact a transcription factor of the basic domain-helix-loop-helix leucine zipper (bHLH-LZ) family. This N-terminal fragment is cleaved by specific proteases and migrates into the nucleus, where it binds to both E boxes (5 -CANNTG-3 ), as do all bHLH proteins, but also to sterol-regulatory element sequences (5 -TCACNCCAC-3 ) [17] .
We have shown that insulin strongly induces the expression of SREBP-1c and increases its nuclear content (reviewed in [1] ). Among other effects, it turns on glucokinase expression, allowing glucose to be metabolized and to generate a signal which activates a glucose-responsive transcription factor. The group of Uyeda has purified this glucose-responsive transcription factor from rat liver, based on its capacity to bind to the glucose-response element of the L-PK promoter, and named it ChREBP (carbohydrate-responseelement-binding protein) [18] . This factor is a bHLH-LZ protein with a bipartite nuclear localization signal. ChREBP is located in the cytoplasm when the glucose concentration is low and enters into the nucleus at high glucose concentrations [19] . It has been proposed that this is secondary to the dephosphorylation of a specific serine (Ser-166), otherwise phosphorylated by protein kinase A under conditions of high cAMP concentrations such as fasting. A second protein kinase A phosphorylation site near the DNA-binding domain, and which precludes ChREBP binding, would also be dephosphorylated in the presence of a high glucose concentration [19] . It is only when both SREBP1c and ChREBP occupy their respective response elements on the promoter of glucose/insulin-responsive genes that their transcriptions become active [7] .
AMPK has been shown to interfere with the action of both SREBP-1c and ChREBP. Activation of AMPK activity in the liver or in cultured hepatocytes leads to a strong decrease in the concentration of SREBP-1c mRNA and hence in the nuclear form of SREBP-1c [20] . We have recent data (D. Azzout-Marniche, E. Duplus, P. Ferré and F. Foufelle, unpublished work) suggesting that in addition to a decreased mRNA concentration, AMPK could also decrease the efficiency of the mature form of SREBP-1c, possibly by increasing the SREBP-1c degradation rate. Whether SREBP1c is a direct target of AMPK is as yet unknown.
Concerning ChREBP, it was demonstrated that an increased activity of AMPK in hepatocytes strongly decreased the transcriptional activity of ChREBP. AMPK specifically phosphorylated Ser-568 of ChREBP, resulting in inactivation of its DNA-binding activity to the glucose-response element of the L-PK promoter [21] . A S568A mutant of the ChREBP gene showed tight DNA binding, whereas a S568D mutant, which mimics the phosphorylation at Ser-568 by AMPK, showed weak DNA binding and was unable to activate L-PK promoter transcriptional activity [21] .
Another hepatic transcription factor involved in L-PK gene expression, hepatocyte nuclear factor (HNF) 4α, has been described as a downstream target of AMPK [22] . When AMPK is activated by AICAR in primary cultured hepatocytes, it leads to the disappearance of HNF4α protein and to a decrease in the expression of all HNF4α-dependent genes tested, including non-glucose-responsive genes such as HNF1, ApoB and ApoCIII. Interestingly, HNF4α mRNA concentration is not affected, suggesting a translational or post-translational event [22] .
A role for AMPK in gluconeogenic gene expression
Since AMPK is usually considered as part of a mechanism involved in energy sparing, a potential role for AMPK in the regulation of the energy-consuming process of hepatic gluconeogenesis (de novo synthesis of glucose from threecarbon precursors) has been considered. The effect of AICAR on phosphoenolpyruvate carboxykinase (PEPCK) expression, a key gluconeogenic enzyme, in cell lines and cultured or incubated hepatocytes has been studied and has yielded conflicting results (from decreased to increased expression) [13, 23, 24] . In our hands, using primary cultured hepatocytes, an increase in AMPK activity using the constitutively active form of the kinase decreases glucagon-induced PEPCK expression (D. Azzout-Marniche, M. Foretz, P. Ferré and F. Foufelle, unpublished work). Glucose-6-phosphatase (G6Pase) is another important enzyme involved in hepatic glucose production which yields free glucose from glucose 6-phosphate arising from both the gluconeogenic and glycogenolytic pathways. AICAR or energy-depletionmediated increases in AMPK activity lead to decreased expression of G6Pase in hepatic cell lines. G6Pase expression is dependent upon the nuclear presence of a transcription factor called forkhead-related protein (FKHR), a member of the Fox family of transcription factors [1] . Activation of AMPK activity in HepG2 cells leads to a strong repression of G6Pase expression [24, 25] and to an almost complete disappearance of the FKHR protein [25] . Since FKHR mRNA is not affected, it again suggests a translational or posttranslational event. Interestingly, the transcriptional activity of AFX (ALL1 fused gene from chromosome X) ζ , another member of the Fox family is also repressed when AMPK activity is increased in hepatoma cell lines [25] .
Are other transcriptional actors involved in AMPK's effects on gene transcription?
An effect of AMPK has been described on p300, a transcriptional co-activator that mediates the activity of many nuclear receptors including the peroxisome-proliferatoractivated receptors [26] . p300 is phosphorylated by AMPK on Ser-89 and this phosphorylation reduces the capacity of p300 to interact in vitro and in vivo with the peroxisomeproliferator-activated receptor γ , the thyroid receptor, the retinoic acid receptor and the retinoid X receptor. However its capacity to interact with non-nuclear-receptor transcription factors is not affected. This AMPK-p300 interaction is addressed in more detail by Leff [27] .
It must be pointed out that if this effect of AMPK is confirmed in functional studies in vivo on genes that are targets of nuclear receptors, it would undoubtedly have profound consequences for the consideration of AMPK as a potential target in Type 2 diabetes.
Concluding remarks
It is now clearly established that AMPK, like its yeast counterpart Snf1, is able to modulate gene expression. In the liver, it affects the genes involved in energy metabolism, although a non-candidate gene approach to explore other potential targets is still lacking. An effect of AMPK on several transcription factors has been described and the mechanisms include decreased mRNA expression, decreased protein abundance and impairment of protein function due to specific phosphorylation. Some of these effects could be explained by effects of AMPK on mRNA half-life through the modulation of nuclear abundance of the RNA-binding protein HuR [28] or on proteins involved in the regulation of protein synthesis such as elongation factor 2 [29] . One burning question that remains is whether AMPK has a physiological role in the longterm regulation of hepatic metabolism. Indeed, it is not yet clear under which circumstances AMPK could be activated in the liver.
It is too early to draw conclusions regarding the beneficial or detrimental long-terms effects of an activator of AMPK on gene expression if it were used as a treatment for Type 2 diabetes. Indeed, AMPK has both insulin-like (e.g. on PEPCK and G6Pase) and insulin-antagonistic (e.g. FAS and L-PK) effects on gene expression. Decreasing hepatic glucose and lipid output is positive from an anti-diabetic perspective but we must await a more systematical search for AMPK responsive genes before we can draw any sound conclusions.
